Antimicrobial treatment of chronic osteomyelitis

Clinical Orthopaedics and Related Research

Volumn 360, Issue , 1999, Pages 47-65

  Mader, Jon T ^a,b,c   Shirtliff, Mark E ^a,c   Bergquist, Stephen C ^a   Calhoun, Jason ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TICARCILLIN; TIMENTIN; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CHRONIC OSTEOMYELITIS; CONFERENCE PAPER; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOLYTIC ANEMIA; HUMAN; HYPERBARIC OXYGEN; LEUKOPENIA; PHLEBITIS; PRIORITY JOURNAL; SEIZURE; VOMITING;

EID: 0033066765     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-199903000-00008     Document Type: Conference Paper

References (105)

1. Archer GL: Antimicrobial susceptibility and selection or resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices. Antimicrob Agents Chemother 14:353-359, 1978.
2. Babul N, Pasko M: Teicoplanin: A new glycopeptide antibiotic complex. Drug Intell Clin Pharm 22:218-226, 1988.
3. Blumberg HM, Rimland D, Carroll DJ, et al: Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 163:1279-85, 1991.
4. Brown GL, Thompson PD, Mader JT, et al: Effects of hyperbaric oxygen upon Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans. Aviat Space Environ Med 50:717-720, 1973.
5. Bryson VJ, Connor JD, Leclere M, Gimmmona ST: High dose oral dicloxacillin treatment of acute staphylococcal osteomyelitis in childhood. J Pediatr 94:673-675, 1979.
6. Bushby SRM: Synergy of Trimethoprim and Sulfonamides: History and Current Status. In Woodbine D (ed). Antibiotics and Antibiosis in Agriculture. London, Butterworths 64-81, 1977.
7. Calhoun JH, Mader JT: Treatment of osteomyelitis with a biodegradable antibiotic implant. Clin Orthop 341:206-214, 1997.
8. Chant C, Rybak M: Quinupristin/dalfopristin (RP 59500): A new streptogramin antibiotic. Ann Pharmacother 29:1022-1027, 1995.
9. Cierny G, Mader JT: Adult chronic osteomyelitis. Orthopedics 7:1557-1564, 1984.
10. Cripps M, Shirtliff ME, Mader JT: The Treatment of osteomyelitis with a hydroxyapatite antibiotic implant in a rabbit model. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 1998.
11. David WH, Mark PM: Bacterial osteomyelitis in adults: Evolving considerations in diagnosis and treatment. Am J Med 101:550-561, 1996.
12. Davis JC, Heckman JD, DeLee JC, et al: Chronic non-hematogenous osteomyelitis treated with adjuvant hyperbaric oxygen. J Bone Joint Surg 68A:1210-1217, 1986.
13. Dresser LD, Rybak MJ: The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18:456-462, 1998.
14. Ericcson HM, Sherris, JC: Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand 227(Suppl B):1-90, 1971.
15. Ernst ME, Ernst EJ, Klepser ME: Levofloxacin and trovafloxacin: The next generation of fluoroquinolones Am J Health Syst Pharm 54: 2569-2584, 1997.
16. Faville RJ, Zaske DE, Kaplan EL: Staphylococcus aureus endocarditis: Combined therapy with vancomycin and rifampin. JAMA 240:1963-1965, 1978.
17. Fong IW, Engelking ER, Kirby WMM: Relative inactivation by Staphylococcus aureus of eight cephalosporin antibiotics. Antimicrob Agents Chemother 9:939-944, 1976.
18. Fraser JH, Helfrich MH, Wallace HM, Ralston SH: Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvarieae. Bone 19:223-226, 1996.
19. Fu KP, Neu HC: Piperacillin a new penicillin active against many bacterial resistant to other penicillins. Antimicrob Agents Chemother 13: 358-367, 1987.
20. Fuller RE, Drew RH, Perfect JR: Treatment of vancomycin-resistant enterococci with a focus on quinupristin-dalfopristin. Pharmacotherapy 16: 584-592, 1996.
21. Garvin KL, Miyano JA, Robinson D, et al: Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis: A canine model. J Bone Joint Surg 76A:1500-1506, 1994.
22. Gentry LO, Rodriguez GG: Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 34:40-43, 1990.
23. Geraci JE, Hermans PE: Vancomycin. Mayo Clin Proc 58:88-91, 1983.
24. Goldhaber P: The effect of hyperoxia on bone resorption in tissue culture. AMA Archives Pathol 66:635-641, 1958.
25. Graham DR, Keldermans MM, Klemm LW, et al: Infectious complications among patients receiving home intravenous therapy with peripheral, central or peripherally placed central venous catheter. Am J Med 91:95S-100S, 1991.
26. Gregory EM, Fridovich I: Induction of superoxide dismutase by molecular oxygen. J Bacteriol 114:543-548, 1973.
27. Hall TJ, Chambers TJ: Molecular aspects of osteoclast function. Inflamm Res 45:1-9,1996.
28. Hill GB, Osterhout S: Experimental effects of hyperbaric oxygen on selected clostridial species. In vitro studies. J Infect Dis 125:17-25,1972.
29. Hodgkin UG: Antibiotics in the treatment of chronic staphylococcal osteomyelitis. South Med J 68:817-823,1975.
30. Hunt TK, Pai MP: The effect of varying ambient oxygen tensions on wound metabolism and collagen synthesis. Surg Gynecol Obstet 135:756-758, 1972.
31. Hunt TK, Zederfeldt B, Goldstick TK: Oxygen and healing. Am J Surg 118:521-525, 1969.
32. Ingram C, Eron LJ, Goldberg RI: Antibiotic therapy of osteomyelitis in outpatients. Med Clin North Am 72:723-738, 1988.
33. Jackson MA, Nelson JD: Etiology and medical management of acute suppurative bone and joint infections in pediatric patients. J Pediatr Orthop 2:313-323, 1982.
34. Jordan GW, Kawachi MM: Analysis of serum bactericidal activity in endocarditis, osteomyelitis, and other bacterial infections. Medicine 60:49-61, 1981.
35. Kass EH, Evans DA: Future prospects and past problems in antimicrobial therapy: The role of cefoxitin. Rev Infect Dis 1:1-2, 1979.
36. Kirby WMM, Regamey C: Pharmacokinetics of cefazolin compared with other cephalosporins. J Infect Dis 128(Suppl):341-346, 1973.
37. Kolyvas E, Ahronheim G, Marks MI, et al: Oral antibiotic therapy of skeletal infections in children. Pediatrics 65:867-871, 1980.
38. LeFrock JL, Klainer AS, Chen S, et al: The spectrum of colitis associated with lincomycin and clindamycin therapy. J Infect Dis 131(Suppl):108-115, 1975.
39. Lew DP, Waldvogel FA: Quinolones and osteomyelitis: State-of-the-art. Drugs 49(Suppl 2):100-111, 1995.
40. Mader JT: Fluoroquinolones in Bone and Joint Infections. In Sanders Jr WE, Sanders CC (eds). Fluoroquinolones in the Treatment of Infectious Diseases. Glenview, IL, Physicians & Scientists 71-86, 1990.
41. Mader JT, Adams KR: Experimental Osteomyelitis. In Schlossberg D (ed). Orthopaedic Infection. Springer Verlag Publishers. New York 39-48, 1987.
42. Mader JT, Adams KR, Couch LA, et al: Potentiation of tobramycin by hyperbaric oxygen in experimental Pseudomonas aeruginosa osteomyelitis (Abstract 1331). Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, American Society for Microbiology 1987.
43. Mader JT, Adams KR, Sutton TE: Infectious diseases: Pathophysiology and mechanisms of hyperbaric oxygen. J Hyperbaric Med 2:133-140, 1987.
44. Mader JT, Brown GL, Guckian JC, et al: A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis 142:915-922, 1980.
45. Mader JT, Cantrell JS, Calhoun JH: Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg 72A:104-110, 1990.
46. Mader JT, Guckian JC, Glass DL, et al: Therapy with hyperbaric oxygen for experimental osteomyelitis due to Staphylococcus aureus in rabbits. J Infect Dis 138:312-318, 1978.
47. Mader JT, Hulet WA, Reinarz JA: Potential value of hyperbaric oxygen in inoperable and intra-abdominal sepsis. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York 631, 1980.
48. Mader JT, Ortiz M, Calhoun JH: Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg 13:701-724, 1996.
49. Mainous EG: Osteogenesis enhancement utilizing hyperbaric oxygen therapy. HBO Review 3:181-185,1982.
50. McCord JM, Keele BB, Fridovich I: An enzyme based theory of obligate anaerobiasis: The physiologic function of superoxide dismutase. Proc Natl Acad Sci 68:1024-1027, 1971.
51. Morrey BF, Dunn JM, Heimbach RD, et al: Hyperbaric oxygen and chronic osteomyelitis. Clin Orthop 144:121-127, 1979
52. Murray BE: The life and times of the Enterococcus. Clin Microbiol Rev 3:46-65, 1990.
53. Musher DM, Fletcher T: Tolerant Staphylococcus aureus causing vertebral osteomyelitis. Arch Intern Med 142:631-634, 1982.
54. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (Tentative Standard: M7-T). Villanova, PA 1983.
55. Neu HC: Aminopenicillins: Clinical pharmacology and use in disease states. Int J Clin Pharmacol Biopharm 11:132-144, 1975.
56. Neu HC: Clinical pharmacokinetics in preventive antimicrobial therapy. South Med J 70(Suppl): 14-24, 1977.
57. Neu HC: Carbenicillin and ticarcillin. Med Clin North Am 66:61-77, 1882.
58. Neu HC, Fu KP: Clavulanic acid: A novel inhibitor of Beta lactamase. Antimicrob Agents Chemother 14:650-655, 1978.
59. Neu HC, Garvey GG: Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. Antimicrob Agents Chemother 8: 457-462, 1975.
60. Neu HC, Labthavikul P: Antibacterial activity and beta-lactam stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother 21:11-18, 1982.
61. Neu HC, Labthavikul P: Comparative in vitro evaluation of N-formimidoyl thienamycin against Gram-positive and Gram-negative aerobic and anaerobic species and its β-lactamase stability. Antimicrob Agents Chemother 21:180-187, 1982.
62. Norden CW: Experimental osteomyelitis V. Therapeutic trials with oxacillin and sisomicin alone and in combination. J Infect Dis 137: 155-160,1978.
63. Norden CW: Osteomyelitis. In Mandell GL, Douglas RG, Bennett JE (eds). Principles and Practice of Infectious Diseases. Ed 4. New York, Churchill Livingstone 922-930, 1990.
64. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J: Chronic osteomyelitis caused by Staphylococcus aureus: Controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 79:947-951, 1986.
65. Norden CW, Shinners E, Niederriter K: Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis 153:956-959, 1986.
66. Onorato IM, Axelrod JL: Hepatitis from intravenous high-dose oxacillin therapy. Ann Intern Med 89:497-500, 1978.
67. Parry MF, Folta D: The in vitro activity of mezlocillin, against community hospital isolates in comparison to other penicillins and cephalosporins. J Antimicrob Chemother 11(Suppl):97-102,1983.
68. Pein FD, Vosti KL: Variation in performance of the serum bactericidal test. Antimicrob Agent Chemother 6:300-333, 1974.
69. Pryka RD, Rodvold KA, Rotschafer JC: Teicoplanin: An investigational glycopeptide antibiotic. Clin Pharm 7:647-658, 1988.
70. Reading C, Hepburn P: The inhibition of staphylococcal beta-lactamase by clavulanic acid. Biochem J 179:67-76, 1979.
71. Reller LB, Stratton CW: Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis 136:196-204, 1977.
72. Reynolds AV, Hamilton-Miller JMT, Brumfitt W: Diminished effect of gentamicin under anaerobic and hypercapnic conditions. Lancet 1:447-449, 1976.
73. Richmond MM, Sykes RB: The beta-lactamase of Gram negative bacteria and their possible role. Adv Microb Physiol 9:31-88, 1975.
74. Rosenblatt JE: Laboratory tests used to guide antimicrobial therapy. Mayo Clin Proc 52:611-615, 1977.
75. Rosenblatt JE, Edson RS: Metronidazole. Mayo Clin Proc 58:154-157, 1983.
76. Sabath LD: Staphylococcal to Penicillins and Cephalosporins. In Schlessinger D (ed). Microbiology. Washington, DC, American Microbiological Society 299, 1976.
77. Sabath LD: Chemical and physical factors influencing methicillin resistance of Staphylococcus aureus and Staphylococcus epidermidis. J Antimicrob Chemother 3(Suppl C):47-51, 1977.
78. Sabath LD, Garner C, Wilcox C, Findland M: Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. Antimicrob Agents Chemother 9:962-969, 1976.
79. Sabath LD, Wheeler N, Laveridire M, Blazevic D, Wilkinson BJ: A new type of penicillin resistance of Staphylococcus aureus. Lancet 1:443-447, 1977.
80. Sanders CC, Sanders WE, Goering RV: In vitro studies with SCH 21420 and SCH 22591: Activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci. Antimicrob Agents Chemother 14:178-184, 1978.
81. Schamberg DR, Dillon WI, Terpenning MS, et al: Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother 36:2533-2535, 1992.
82. Schlicter JG, MacLean H: A method of determining the effective therapeutic level in the treatment of subacute bacterial endocarditis with penicillin. Am Heart J 34:209-211, 1947.
83. Schreiner A, Tonjum S, Digranes A: Hyperbaric oxygen therapy in bacteroides infections. Acta Chir Scand 140:73-76, 1974.
84. Scully BE, Neu HC: Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant pseudomonas and other Gram-negative bacteria. Arch Intern Med 144:57-62, 1984.
85. Sheftel TJ, Mader JT, Pennick JJ, Cierny G: Methicillin-resistant Staphylococcus aureus osteomyelitis. Clin Orthop 188:231-239, 1985.
86. Shinto Y, Uchida A, Korkusaz F, Araki N, Ono K: Calcium hydroxyapatite ceramic used as a drug delivery system for antibiotics. J Bone Joint Surg 74B:600-604, 1992.
87. Shirtliff ME, Mohan D, Calhoun JH, Mader JT: Four week intravenous antibiotic therapy versus two week intravenous plus four week oral antibiotic therapy in the treatment of long bone osteomyelitis. Musculoskeletal Infection Society Annual Meeting, Snowmass, CO 1997.
88. Shlaes DM, Binczewski B: Enterococcal resistance to vancomycin and related cyclic glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 9:106-110,1990.
89. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R: Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 97:344-350, 1982.
90. Stratton CW, Reller LB: Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. J Infect Dis 136:187-195, 1977.
91. Summersgill JT, Schupp LG, Raff MJ: Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam into bone. Antimicrob Agents Chemother 21:601-603, 1982
92. Sutter VL: In vitro susceptibility of anaerobes: Comparison of clindamycin and other antimicrobial agents. J Infect Dis 135(Suppl):7-12, 1977.
93. Sykes RB, Bonner DP, Bush K: Aztreonam: A synthetic monobactam active against aerobic Gram-negative bacteria. Antimicrob Agents Chemother 21:85-92, 1982.
94. Tetzloff TR, McCracken GH, Nelson FD: Oral antibiotic therapy for skeletal infections in children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr 92:485-490, 1978.
95. Thornsberry C: Review of in vitro activity of third-generation cephalosporins and other newer Beta-lactam antibiotics against clinically important bacteria. Am J Med 79(Suppl 2A):14-20, 1985.
96. Verklin RM, Mandell GL: Alteration of effectiveness of antibiotics by anaerobiosis. J Lab Clin Med 89:65-71, 1977.
97. Wagstaff AJ, Balfour JA: Grepafloxacin. Drugs 825-827, 1997.
98. Waldvogel FA, Medoff G, Swartz MN: Osteomyelitis: A review of clinical features, therapeutic consideration, and unusual aspect. N Engl J Med. 282:260-266, 1970.
99. Wallyn RJ, Gumbiner SH, Goldfein S, et al: Treatment of anaerobic infections with hyperbaric oxygen. Surg Clin North Am 44:107-112, 1964.
100. Ward TT, Winn RE, Hartstein AI, Sewell DL: Observations relating to an inter-hospital outbreak of methicillin-resistant Staphylococcus aureus: Role of antimicrobial therapy in infection control. Infect Control 2:453-459, 1981.
101. Wilson SG, Sanders CC: Selection and characterization of strains of Staphylococcus aureus displaying unusual resistance to aminoglycosides. Antimicrob Agents Chemother 10:519-525, 1976.
102. Wormser GP, Keusch GT: Trimethoprim-sulfamethoxazole in the United States. Ann Intern Med 91:420-429, 1979.
103. Yablon IG, Cruess RL: The effect of hyperbaric oxygen on fracture healing in rats. 8: 186-202,1968.
104. Yow MD, Taber LH, Barrett FF, et al: A ten-year assessment of methicillin-associated side-effects. Pediatrics 58:329-334, 1976.
105. Zhang X, Wyss UP, Pichora D, Goosen MP: Biodegradable controlled antibiotic release devices for osteomyelitis: Optimization of release properties. J Pharm Pharmacol 46:718-724, 1994.